Pharmaceuticals

THDB

THDB released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 747.65 M (forecast CNY 793.93 M), actual EPS CNY 0.06 (forecast CNY 0.06)

THDB to release FY2026 Q1 earnings on April 29 After-Market BJT, forecast revenue CNY 793.93 M, EPS CNY 0.06

THDB released FY2025 Q4 earnings on April 19 After-Market (BJT), actual revenue CNY 767.64 M (forecast CNY 581.97 M), actual EPS CNY 0.0086 (forecast CNY 0.04)

THDB released FY2025 Annual Earnings on April 19 After-Market (BJT), actual revenue CNY 2.947 B (forecast CNY 2.834 B), actual EPS CNY 0.62 (forecast CNY 0.64)

THDB to Release FY2025 Earnings on April 20 After-Market (BJT), Forecast Revenue CNY 2.834 B, EPS CNY 0.64

THDB released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 806.1 M (forecast CNY 723.61 M), actual EPS CNY 0.5039 (forecast CNY 0.1)

THDB released FY2025 9 Months Earnings on October 27 After-Market (BJT), Actual Revenue CNY 1.458 B, Actual EPS CNY 0.5639

THDB to Release FY2025 Q3 Earnings on October 28 After-Market (BJT), Forecast Revenue CNY 723.61 M, EPS CNY 0.1

THDB released FY2025 Q2 earnings on August 25 During-Market (BJT), actual revenue CNY 0 (forecast CNY 654.49 M), actual EPS CNY 0 (forecast CNY 0.06)

THDB released FY2025 Semi-Annual Earnings on August 25 During-Market (BJT), actual revenue CNY 1.373 B, actual EPS CNY 0.11

THDB FY2025 Semi-Annual Earning Release on August 26, 2025 (BJT)

Tonhguangdongbao Reports First Annual Loss in 2024

Tonghua Dongbao Reports H1 Net Profit of 217.3 Million Yuan

Tonghua Dongbao Plans to Transfer 5.7% of Tebo Biopharma Shares

Tonghua Dongbao Obtains Registration Certificate for Human Insulin Injection in Nicaragua

Trump to Sign Executive Order Lowering Drug Prices

Tonghua Dongbao Inc. Recorded an Annual Net Loss of 42.7 Million RMB

THDB released FY2025 Q1 earnings on April 29 Pre-Market (BJT), actual revenue CNY 651.5 M (forecast CNY 649.06 M), actual EPS CNY 0.06 (forecast CNY 0.06)

THDB released FY2024 Annual Earnings on April 29 After-Market (BJT), actual revenue CNY 2.01 B (forecast CNY 2.075 B), actual EPS CNY -0.02 (forecast CNY 0.0175)

THDB released FY2024 Q4 earnings on April 29 After-Market (BJT), actual revenue CNY 561.88 M (forecast CNY 551.67 M), actual EPS CNY 0.0139 (forecast CNY 0.05)

600867

THDB recently obtained the product registration certificate for insulin aspart injection issued by the Indonesian Food and Drug Authority, with registration number DKI2570600143A1. This medication is a rapid-acting insulin primarily used to control postprandial blood sugar levels. The acquisition of this registration certificate will help THDB expand its international market, enhance its brand image, and strengthen its competitiveness in emerging markets

Zhitong

THDB: The winter insulin injection has obtained an overseas drug registration certificate

On October 17, 2025, Tonghua Dongbao held a board meeting to review and approve the share repurchase plan, and announced the situation of the top ten shareholders and the top ten unrestricted shareholders on the trading day prior to the share repurchase resolution. Dongbao Industrial Group Co., Ltd. holds 613,823,496 shares, accounting for 31.34%; Tianjin Zhenyi Equity Investment Partnership holds 183,058,967 shares, accounting for 9.35%. All shares are unrestricted circulating shares, and the top 10 shareholders are consistent with the top 10 unrestricted shareholders

THDB: Announced the shareholding status of the top ten shareholders and the top ten unrestricted shareholders before the share repurchase

According to the Zhitong Finance APP, Tonghua Dongbao announced that the company has decided to use its own funds to repurchase company shares for the employee stock ownership plan and/or equity incentive. The amount for this share repurchase will not be less than RMB 20 million (inclusive) and not more than RMB 40 million (inclusive), with the repurchase price not exceeding RMB 10 per share (inclusive)

THDB plans to repurchase company shares for between 20 million and 40 million yuan

According to the Zhitong Finance APP, THDB announced that the company recently received the marketing authorization for its product Insulin Glargine Injection issued by the Ministry of Health of the Republic of the Union of Myanmar. Insulin Glargine is a long-acting insulin analog product that is injected once daily, with an effect duration of up to 24 hours after injection, providing a peakless blood concentration and steadily lowering the patient's blood sugar levels

THDB: Insulin Glargine Injection has obtained overseas listing approval

On October 9th, THDB held a performance briefing for the first half of 2025, stating that the domestic insulin market will continue to develop steadily over the next three years. The company is continuously developing new products, such as ultra-fast-acting insulin, degludec insulin liraglutide injection, and GLP-1/GIP dual-target receptor agonists, as well as expanding into new therapeutic areas, such as weight loss and gout, to continuously explore new market space and promote the company's long-term high-quality development

THDB: The domestic insulin market will continue to develop steadily in the next three years

603087

China Galaxy Securities released a research report indicating that the diabetes drug market is vast, with GLP-1 class drugs experiencing explosive growth due to their dual advantages of lowering blood sugar and weight loss. It is expected that the global market size will exceed USD 50 billion in 2024, while the Chinese market was CNY 8.7 billion in 2023 and is expected to increase to CNY 23.3 billion by 2025. The industry is evolving towards long-acting, multi-target, and innovative dosage forms, with significant potential for domestic substitution. Innovation has become the core theme, and the prospects for leading enterprises are promising

Gan & Lee

China Galaxy Securities: The future domestic substitution space for diabetes is broad, and innovation is expected to achieve a curve overtaking

THDB plans to implement an employee stock ownership plan in 2025, with a maximum of 77 participants and a fundraising cap of 47.52383 million yuan. The total number of shares to be acquired under the plan will not exceed 11.07782 million shares, accounting for 0.566% of the company's equity. The initial acquisition portion will be 9.29 million shares, accounting for 83.861%. Reserved shares will not exceed 1.78782 million shares, accounting for 16.139%. The acquisition price is set at 4.29 yuan per share, and it will not be lower than 50% of the average trading price prior to the announcement

THDB plans to launch an employee stock ownership plan in 2025

According to the Zhitong Finance APP, Tonghua Dongbao disclosed its semi-annual report for 2025, reporting revenue of 1.373 billion yuan, a year-on-year increase of 85.6%; net profit attributable to shareholders of 218 million yuan, turning from loss to profit year-on-year; net profit excluding non-recurring gains and losses of 221 million yuan, also turning from loss to profit year-on-year; basic earnings per share of 0.11 yuan

THDB released its semi-annual performance, with a net profit attributable to the parent company of 218 million yuan, turning a profit from a loss year-on-year

THDB announced that the company's board of directors recently received a written resignation letter from General Manager Leng Chunsheng, who resigned from his position due to adjustments in work arrangements and the development needs of the affiliated company Junhe Alliance Biopharmaceuticals. After resigning, Mr. Leng Chunsheng will continue to serve as the company's Vice Chairman and has been appointed as Chief Scientific Advisor. The company's board of directors has agreed to appoint Mr. Li Jiahong as the company's General Manager, with a term ending when the 11th Board of Directors' term expires

THDB: General Manager Leng Chunsheng resigns

THDB: Preliminary net profit data for the first half of the year is RMB 217.3 million

THDB(600867.SH)